January 4, 2025 Top High-Yield Dividend Stocks To Watch For 2025
December 22, 2024 What About Federal Reserve Rates Cut?
December 20, 2024 Honda-Nissan Alliance: A Bold Move To Dominate Auto Industry
December 13, 2024 Trump’s Plan: Potential Shake-Up For Bank Regulators
Tesla: High Hopes, Low Deliveries
Nvidia: Don’t Expect Major Gains From Here (Technical Analysis)
3M Company: Laying The Groundwork For Margin Expansion
Pop Goes The Tesla (Our Top Short For 2025)
Apple: A Piece Of This Pie Is Too Expensive For Me
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
December 21, 2024 Best AI Trading & Performance Tools
December 21, 2024 Best Economic Calendars For Traders
December 9, 2024 When to Switch Payroll Solutions and How to Make a Smooth Transition
Novavax (NVAX) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: January 18, 2025 (07:54)
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
Analysts predictions
Full report|
This Week
|
Neutral | Opinions: Na |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Neutral | Opinions: Na |
|
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2025, 2026, 2027. How much will one Novavax share be worth in 2025 - 2027?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
Novavax, Inc. Analysts predictions review
As of now, Panda has combed through 0 analytical articles which are directly related to NVAX from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 0 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Jan 01, 1970 to Jan 01, 1970.
Novavax's Restructuring Moves: Navigating Uncertainty with Sanofi Partnership
In this review, we delve into Brendan O'Boyle's analytical financial article, which takes a Neutral stance on NVAX stock. O'Boyle, a seasoned contributor since 2012, has crafted 95 insightful publications, earning the trust of 1267 subscribers. With an impressive ratio of publications over his active years, O'Boyle has continuously offered reliable insights in the financial realm. His perspectives are regarded with high credibility, positioning him as a respected voice amongst readers and industry enthusiasts alike. This reputation ensures that his neutral analysis of NVAX stock is both well-considered and balanced, providing readers with a dependable evaluation free from undue bias or extreme opinion. Through this review, we aim to highlight the strengths of O’Boyle's latest publication and its implications for investors.
Key Theses of Novavax Analysis
- Novavax reported better than expected Q3 earnings but cut its 2024 full-year guidance due to lower COVID-19 vaccine sales.
- The company is undergoing significant restructuring to focus on key value drivers including a promising collaboration with Sanofi.
- The Sanofi partnership provides potential growth via milestone payments, despite the current uncertainties and restructuring.
- The lifted clinical hold on its COVID-19/influenza combination is a positive step towards future growth.
- The stock is considered a 'hold' with potential for significant upside if key initiatives succeed.
Factors Influencing NVAX Stock Price
Reduction in 2024 Full-Year Guidance
The downward revision in guidance due to lower COVID-19 vaccine sales was a primary reason for the stock's decline, indicating significant impact on investor sentiment and stock valuation in the short term.
Partnership with Sanofi
The partnership provides a potential up to $700 million in milestone payments, creating a substantial positive influence on Novavax's financial outlook and investor expectations.
Decline in Revenue since 2022
The steady decline in revenue to a potential 2024 midpoint of $675 million severely impacts the stock’s attractiveness, representing only 34% of its peak during the pandemic, which weakens growth prospects.
Lifting of Clinical Hold on COVID-19/Influenza Combination
The ability to progress to a Phase III study removes previous development barriers and potentially opens avenues for new revenue streams, albeit not immediately impactful.
Substantial Cost Reduction Program
The cost reduction plan aims to stabilize operations by aligning expenses with reduced revenue, potentially enhancing profitability, but signifies restructuring uncertainty in the near-term.
Review the original Analysis
Novavax Faces Uncertain Future Despite Sanofi Partnership Safety Net
In this analytical financial article, seasoned author Edmund Ingham critically evaluates NVAX stock, expressing a Bearish outlook. With a solid base of 12,446 subscribers and an impressive 858 publications since 2018, Ingham demonstrates remarkable productivity and engagement in his field. His consistent publication frequency signals deep expertise, offering well-regarded insights to his audience. Furthermore, Ingham's work is characterized by a remarkable degree of credibility, ranking within the realm of highly authoritative opinions. Readers can trust his educated assessments and detailed analyses. As you delve into this review, prepare to encounter a meticulously reasoned perspective that is both popular and trusted within the financial community.
Key Theses of the Review
- Novavax's upcoming Q3 earnings report is crucial for determining its financial health.
- The Sanofi partnership provides a lifeline with upfront payments and potential royalties, but limits Novavax's direct revenue from their vaccine.
- Novavax's late entrance into the COVID vaccine market resulted in heavy losses compared to competitors.
- Novavax faces uncertain future revenue streams beyond its Sanofi partnership and COVID-related royalties.
Factors Influencing NVAX Stock Price
Sanofi Partnership and Royalties
The Sanofi partnership provides Novavax with financial stability through upfront payments and potential milestone royalties, which is essential given its recent financial struggles. However, it limits Novavax's control over future revenue, making its own strategic growth opportunities less impactful.
Delayed Market Entry and Initial Losses
Novavax's delayed entry into the COVID vaccine market resulted in being overshadowed by major competitors, Moderna and Pfizer. This severely affected its earnings potential when demand was at its peak, leading to significant financial losses.
FDA Clinical Hold on COVID/Influenza Combo Vaccine
The FDA's clinical hold adds uncertainty to Novavax's proprietary pipeline, potentially stalling new revenue streams. This affects investor confidence as it delays potential future earnings from new products.
Future Market for COVID Vaccines
The long-term market for COVID vaccines remains uncertain, affecting potential revenue from the Sanofi agreement. If the market stabilizes or shrinks, Novavax's received royalties could underperform expectations.
Cash Position and Current Financial Stability
A strong cash position post-Sanofi payment boosts near-term financial stability for Novavax, providing a buffer against operational costs and potential investment in pipeline developments. However, reliance on this position without new revenue would eventually diminish its impact.
Review the original Analysis
Commentary
The upcoming Q3 earnings report is a critical moment for Novavax, bringing their financial health into sharp focus. Their collaboration with Sanofi, while providing some financial stability, limits their independent growth potential, highlighting their ongoing struggle to establish a strong market presence. Novavax was late to the COVID vaccine game, and it shows. Their significant losses compared to early movers like Pfizer and Moderna paint a picture of a company trying to play catch up in a market that's already matured. In the short term, the influence of these factors is relatively high, reflecting a Bearish outlook over the next 15 days as investors remain cautious about the company's earnings capabilities.
Looking further ahead, the longer-term picture remains clouded with uncertainty. The delayed entry into critical vaccine markets and the added complication of an FDA clinical hold on potentially lucrative new products cast doubt on Novavax's strategic position. While the current cash infusion provides a temporary shield, the reliance on the Sanofi partnership and an unstable COVID vaccine market doesn't bode well. These factors suggest that Novavax's stock may continue to face downward pressure in the coming month as the average influence signals a Bearish trend overall.
Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan 20 | 9.26 | 8.96 | 9.42 | 5.11 |
| Jan 21 | 9.51 | 9.06 | 9.93 | 9.54 |
| Jan 22 | 9.85 | 9.40 | 10.11 | 7.55 |
| Jan 23 | 10.03 | 9.56 | 10.46 | 9.44 |
| Jan 24 | 10.15 | 9.93 | 10.54 | 6.07 |
| Jan 25 | 9.91 | 9.33 | 10.24 | 9.85 |
| Jan 26 | 10.28 | 9.92 | 11.02 | 11.10 |
| Jan 27 | 10.52 | 10.02 | 11.13 | 11.06 |
| Jan 28 | 10.14 | 9.50 | 10.85 | 14.22 |
| Jan 29 | 9.77 | 9.25 | 10.08 | 9.03 |
| Jan 30 | 9.36 | 8.92 | 9.82 | 10.01 |
| Jan 31 | 10.20 | 9.66 | 10.67 | 10.55 |
| Feb 01 | 10.69 | 10.18 | 11.41 | 12.10 |
| Feb 02 | 11.59 | 11.07 | 11.99 | 8.39 |
| Feb 03 | 11.48 | 11.16 | 12.12 | 8.61 |
| Feb 04 | 11.10 | 10.47 | 11.78 | 12.50 |
| Feb 05 | 11.42 | 10.93 | 12.23 | 11.95 |
| Feb 06 | 12.29 | 11.93 | 13.18 | 10.48 |
| Feb 07 | 12.45 | 12.11 | 13.21 | 9.07 |
| Feb 08 | 12.10 | 11.72 | 12.94 | 10.41 |
| Feb 09 | 11.57 | 11.26 | 12.04 | 6.94 |
| Feb 10 | 11.26 | 11.01 | 11.94 | 8.46 |
| Feb 11 | 11.85 | 11.44 | 12.11 | 5.88 |
| Feb 12 | 11.86 | 11.39 | 12.38 | 8.62 |
| Feb 13 | 12.15 | 11.38 | 12.60 | 10.77 |
| Feb 14 | 12.95 | 12.23 | 13.20 | 7.91 |
| Feb 15 | 12.75 | 12.36 | 13.15 | 6.41 |
| Feb 16 | 11.93 | 11.65 | 12.50 | 7.28 |
| Feb 17 | 11.88 | 11.04 | 12.67 | 14.82 |
| Feb 18 | 11.17 | 10.37 | 11.65 | 12.31 |
Novavax Daily Price Targets
Novavax Stock Forecast 01-20-2025.
Forecast target price for 01-20-2025: $9.26.
Positive dynamics for Novavax shares will prevail with possible volatility of 4.862%.
Pessimistic target level: 8.96
Optimistic target level: 9.42
Novavax Stock Forecast 01-21-2025.
Forecast target price for 01-21-2025: $9.51.
Positive dynamics for Novavax shares will prevail with possible volatility of 8.706%.
Pessimistic target level: 9.06
Optimistic target level: 9.93
Novavax Stock Forecast 01-22-2025.
Forecast target price for 01-22-2025: $9.85.
Positive dynamics for Novavax shares will prevail with possible volatility of 7.017%.
Pessimistic target level: 9.40
Optimistic target level: 10.11
Novavax Stock Forecast 01-23-2025.
Forecast target price for 01-23-2025: $10.03.
Positive dynamics for Novavax shares will prevail with possible volatility of 8.627%.
Pessimistic target level: 9.56
Optimistic target level: 10.46
Novavax Stock Forecast 01-24-2025.
Forecast target price for 01-24-2025: $10.15.
Positive dynamics for Novavax shares will prevail with possible volatility of 5.724%.
Pessimistic target level: 9.93
Optimistic target level: 10.54
Novavax Stock Forecast 01-25-2025.
Forecast target price for 01-25-2025: $9.91.
Negative dynamics for Novavax shares will prevail with possible volatility of 8.963%.
Pessimistic target level: 9.33
Optimistic target level: 10.24
NVAX (NVAX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Feb. | 10.78 | 8.87 | 12.30 | 27.87 |
| Mar. | 10.65 | 8.31 | 12.31 | 32.44 |
| Apr. | 12.15 | 11.02 | 13.28 | 17.02 |
| May. | 13.90 | 11.77 | 15.94 | 26.16 |
| Jun. | 15.40 | 13.00 | 18.82 | 30.93 |
| Jul. | 18.12 | 14.32 | 22.15 | 35.35 |
| Aug. | 20.62 | 17.28 | 24.34 | 28.98 |
| Sep. | 20.38 | 17.26 | 21.60 | 20.09 |
| Oct. | 18.73 | 15.41 | 21.03 | 26.71 |
| Nov. | 24.34 | 20.98 | 28.58 | 26.58 |
| Dec. | 25.44 | 20.40 | 31.39 | 35.01 |
Novavax forecast for this year
Novavax Stock Prediction for Feb 2025
An uptrend is forecast for this month with an optimal target price of $10.7758. Pessimistic: $8.87. Optimistic: $12.30
Novavax Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $10.6465. Pessimistic: $8.31. Optimistic: $12.31
Novavax Stock Prediction for Apr 2025
An uptrend is forecast for this month with an optimal target price of $12.1477. Pessimistic: $11.02. Optimistic: $13.28
Novavax Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $13.897. Pessimistic: $11.77. Optimistic: $15.94
Novavax Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $15.3978. Pessimistic: $13.00. Optimistic: $18.82
Novavax Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $18.1232. Pessimistic: $14.32. Optimistic: $22.15
Novavax Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $20.6242. Pessimistic: $17.28. Optimistic: $24.34
Novavax Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $20.3768. Pessimistic: $17.26. Optimistic: $21.60
Novavax Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $18.7262. Pessimistic: $15.41. Optimistic: $21.03
Novavax Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $24.3441. Pessimistic: $20.98. Optimistic: $28.58
Novavax Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $25.4396. Pessimistic: $20.40. Optimistic: $31.39
Novavax (NVAX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 20.10 | 18.53 | 22.39 | 17.24 |
| Feb | 25.76 | 21.05 | 31.64 | 33.47 |
| Mar | 30.09 | 27.20 | 35.69 | 23.78 |
| Apr | 36.68 | 29.20 | 40.21 | 27.37 |
| May | 40.10 | 31.80 | 46.47 | 31.58 |
| Jun | 38.53 | 30.21 | 41.31 | 26.87 |
| Jul | 41.77 | 38.64 | 49.66 | 22.20 |
| Aug | 52.92 | 44.82 | 58.00 | 22.72 |
| Sep | 44.35 | 41.42 | 53.93 | 23.19 |
| Oct | 45.01 | 37.18 | 51.90 | 28.36 |
| Nov | 49.74 | 44.22 | 55.11 | 19.77 |
| Dec | 46.16 | 39.65 | 49.76 | 20.32 |
Novavax (NVAX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 50.03 | 38.93 | 55.74 | 30.16 |
| Feb | 44.18 | 39.28 | 53.33 | 26.35 |
| Mar | 47.49 | 43.50 | 56.76 | 23.35 |
| Apr | 42.08 | 36.65 | 45.99 | 20.31 |
| May | 41.45 | 37.59 | 50.03 | 24.86 |
| Jun | 45.93 | 41.52 | 53.64 | 22.60 |
| Jul | 33.53 | 31.31 | 39.46 | 20.65 |
| Aug | 23.87 | 18.21 | 29.10 | 37.41 |
| Sep | 21.29 | 18.29 | 25.12 | 27.20 |
| Oct | 21.68 | 18.49 | 23.30 | 20.65 |
| Nov | 23.89 | 22.02 | 25.96 | 15.18 |
| Dec | 21.09 | 16.41 | 23.50 | 30.16 |
Novavax information and performance
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.
EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Commentary
Novavax's recent earnings report shows the company in a state of transition, as they work towards stabilizing after a disappointing financial outlook. Investors were initially discouraged by the reduced 2024 full-year guidance resulting from decreased COVID-19 vaccine sales, which impacted the stock negatively due to declining investor sentiment. The company's efforts to cut costs and streamline operations aim to realign their revenue and expenditures, providing some hope for improved profitability amidst these challenges.
On a more optimistic note, the partnership with Sanofi and the upcoming potential $700 million in milestone payments injects positive sentiment and hope for the company’s financial health moving forward. Coupling this with the lifting of the clinical hold on its COVID-19/influenza combination points towards possible new revenue streams, albeit over the longer term. Averaging the influence strengths of these factors reveals a score suggesting a balanced near-term outlook, hence assigning the trend as 'Neutral,' with a chance for positivity if strategic initiatives take effect effectively.